# Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

> **NCT05525338** · PHASE4 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 196 (estimated)

## Conditions studied

- Drug Monitoring
- Carcinoma, Non-Small-Cell Lung
- Lung Cancer
- Anaplastic Lymphoma Kinase Gene Mutation
- Anaplastic Lymphoma Kinase Gene Translocation

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT05525338
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-23
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2024-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525338, "Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05525338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*